Risk Factors Predicting Complications of Transvenous Lead Extraction

Figure 2

Kaplan–Meier death-free survival probability in 30-day follow-up depending on (a) failure of clinical success of TLE, (b) indications for TLE (infective versus noninfective), (c) NYHA class before TLE (I,II versus III, IV), and (d) previous unsuccessful attempt to TLE.

(a) The Kaplan-Meier death-free survival probability in 30-day follow-up depending on the indications for TLE (infective versus noninfective), p<0.001

(b) The Kaplan-Meier death-free survival probability in 30-day follow-up depending on chronic renal failure (CRF), p<0.001

(c) The Kaplan-Meier death-free survival probability in 30-day follow-up depending on the NYHA class before TLE (I,II, versus III, IV), p<0.001

(d) The Kaplan-Meier death-free survival probability in 30-day follow-up depending on previous unsuccessful attempt to TLE, p<0.01